6.
Niesel J, Pinto A, Peindy NDongo H, Merz K, Ott I, Gust R
. Photoinduced CO release, cellular uptake and cytotoxicity of a tris(pyrazolyl)methane (tpm) manganese tricarbonyl complex. Chem Commun (Camb). 2008; (15):1798-800.
DOI: 10.1039/b719075a.
View
7.
Gobbo A, Pereira S, Biancalana L, Zacchini S, Saraiva M, Dyson P
. Anticancer ruthenium(II) tris(pyrazolyl)methane complexes with bioactive co-ligands. Dalton Trans. 2022; 51(44):17050-17063.
DOI: 10.1039/d2dt03009h.
View
8.
Berasaluce I, Cseh K, Roller A, Hejl M, Heffeter P, Berger W
. The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo-A Comparison of O,O-, S,O-, and N,N-Chelate Effects. Chemistry. 2019; 26(10):2211-2221.
PMC: 7064950.
DOI: 10.1002/chem.201903605.
View
9.
Massoud S, Louka F, Ducharme G, Fischer R, Mautner F, Vanco J
. Copper(II) complexes based on tripodal pyrazolyl amines: Synthesis, structure, magnetic properties and anticancer activity. J Inorg Biochem. 2017; 180:39-46.
DOI: 10.1016/j.jinorgbio.2017.11.023.
View
10.
Woods J, Cao J, Lippert A, Wilson J
. Characterization and Biological Activity of a Hydrogen Sulfide-Releasing Red Light-Activated Ruthenium(II) Complex. J Am Chem Soc. 2018; 140(39):12383-12387.
PMC: 6599746.
DOI: 10.1021/jacs.8b08695.
View
11.
Min H, Lee H
. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022; 54(10):1670-1694.
PMC: 9636149.
DOI: 10.1038/s12276-022-00864-3.
View
12.
Mansfield A, Fields A, Jatoi A, Qi Y, Adjei A, Erlichman C
. Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs. 2013; 24(10):1079-83.
PMC: 3937851.
DOI: 10.1097/CAD.0000000000000009.
View
13.
Bigmore H, Lawrence S, Mountford P, Tredget C
. Coordination, organometallic and related chemistry of tris(pyrazolyl)methane ligands. Dalton Trans. 2005; (4):635-51.
DOI: 10.1039/b413121e.
View
14.
Mohammadi F, Soltani A, Ghahremanloo A, Javid H, Hashemy S
. The thioredoxin system and cancer therapy: a review. Cancer Chemother Pharmacol. 2019; 84(5):925-935.
DOI: 10.1007/s00280-019-03912-4.
View
15.
Hofheinz R, Dittrich C, Jakupec M, Drescher A, Jaehde U, Gneist M
. Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV). Int J Clin Pharmacol Ther. 2005; 43(12):590-1.
DOI: 10.5414/cpp43590.
View
16.
Maron A, Czerwinska K, Machura B, Raposo L, Roma-Rodrigues C, Fernandes A
. Spectroscopy, electrochemistry and antiproliferative properties of Au(iii), Pt(ii) and Cu(ii) complexes bearing modified 2,2':6',2''-terpyridine ligands. Dalton Trans. 2018; 47(18):6444-6463.
DOI: 10.1039/c8dt00558c.
View
17.
Pullen E, Rabinovich D, Incarvito C, Concolino T, Rheingold A
. Syntheses and structures of methyltris(pyrazolyl)silane complexes of the group 6 metals. Inorg Chem. 2003; 39(7):1561-7.
DOI: 10.1021/ic990945l.
View
18.
Tilsed C, Fisher S, Nowak A, Lake R, Lesterhuis W
. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol. 2022; 12:960317.
PMC: 9372369.
DOI: 10.3389/fonc.2022.960317.
View
19.
Wu S, Wu Z, Ge Q, Zheng X, Yang Z
. Antitumor activity of tridentate pincer and related metal complexes. Org Biomol Chem. 2021; 19(24):5254-5273.
DOI: 10.1039/d1ob00577d.
View
20.
Azam M, Suresh B
. Biological activities of 2-mercaptobenzothiazole derivatives: a review. Sci Pharm. 2012; 80(4):789-823.
PMC: 3528053.
DOI: 10.3797/scipharm.1204-27.
View